References

Adrenal insufficiency in adults: A review

10.1001/jama.2025.5485 · ExternalCitation · doi-reference

Tislelizumab: first approval

10.1007/s40265-020-01286-z · ExternalCitation · doi-reference

Endocrinopathies associated with immune checkpoint inhibitor use

10.1016/j.eprac.2024.03.023 · ExternalCitation · doi-reference

Aptamers as immune checkpoint inhibitors in cancer immunotherapy: Targeting Ctla-4/B7 and Pd-1/Pd-L1 pathways

10.1016/j.intimp.2025.115339 · ExternalCitation · doi-reference

Adrenal insufficiency

10.1016/s0140-6736(21)00136-7 · ExternalCitation · doi-reference

A method for estimating the probability of adverse drug reactions

10.1038/clpt.1981.154 · ExternalCitation · doi-reference

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

10.1073/pnas.1908079116 · ExternalCitation · doi-reference

Immune checkpoint inhibitor-related adrenal hypofunction and psoriasisby induced by tislelizumab: A case report and review of literature

10.1097/md.0000000000037562 · ExternalCitation · doi-reference

Multiple endocrine adverse reactions and pituitary axis dysfunction induced by Pd-1 immunotherapy in an esophageal cancer patient: Case report

10.1097/md.0000000000048449 · ExternalCitation · doi-reference

Cancer immunotherapy using checkpoint blockade

10.1126/science.aar4060 · ExternalCitation · doi-reference

Pituitary expression of Ctla-4 mediates hypophysitis secondary to administration of Ctla-4 blocking antibody

10.1126/scitranslmed.3008002 · ExternalCitation · doi-reference

Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors

10.1136/jitc-2021-002493 · ExternalCitation · doi-reference

Prolonged progression-free survival in a patient with highly pretreated recurrent ovarian cancer after developing multisystem immune-related adverse events: A case report and literature review

10.1159/000546423 · ExternalCitation · doi-reference

Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: A case series and literature review

10.1186/s12890-024-03140-4 · ExternalCitation · doi-reference

Hypophysitis induced by tislelizumab: A case report of somnolence and delirium with elevated eosinophils

10.12659/ajcr.948143 · ExternalCitation · doi-reference

Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (Tislelizumab) therapy in patients with advanced gastric cancer: Two case reports

10.12701/yujm.2021.00934 · ExternalCitation · doi-reference

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

10.1530/eje-19-0238 · ExternalCitation · doi-reference

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An Ese clinical practice guideline

10.1530/eje-22-0689 · ExternalCitation · doi-reference

Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: A systematic review and meta-ethnography of case reports

10.3389/fendo.2025.1636452 · ExternalCitation · doi-reference

Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: New insights into anti-corticotroph antibody

10.3389/fimmu.2023.1284301 · ExternalCitation · doi-reference

Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: A case report and literature review

10.3389/fimmu.2023.1295310 · ExternalCitation · doi-reference

Case report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: A case series

10.3389/fimmu.2025.1516297 · ExternalCitation · doi-reference

Immune-related adverse events associated with immune checkpoint inhibitors: A scoping review

10.3390/ph19020276 · ExternalCitation · doi-reference

Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: Diagnostic challenges and link with survival

10.6004/jnccn.2022.7098 · ExternalCitation · doi-reference

Immunotherapy-induced hypophysitis following treatment with tislelizumab in an elderly patient with bladder cancer and prostate cancer: A case report

10.7759/cureus.51015 · ExternalCitation · doi-reference